Skip to main content

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.

Publication ,  Journal Article
Armstrong, PW; Gershlick, AH; Goldstein, P; Wilcox, R; Danays, T; Lambert, Y; Sulimov, V; Rosell Ortiz, F; Ostojic, M; Welsh, RC; Carvalho, AC ...
Published in: N Engl J Med
April 11, 2013

BACKGROUND: It is not known whether prehospital fibrinolysis, coupled with timely coronary angiography, provides a clinical outcome similar to that with primary percutaneous coronary intervention (PCI) early after acute ST-segment elevation myocardial infarction (STEMI). METHODS: Among 1892 patients with STEMI who presented within 3 hours after symptom onset and who were unable to undergo primary PCI within 1 hour, patients were randomly assigned to undergo either primary PCI or fibrinolytic therapy with bolus tenecteplase (amended to half dose in patients ≥75 years of age), clopidogrel, and enoxaparin before transport to a PCI-capable hospital. Emergency coronary angiography was performed if fibrinolysis failed; otherwise, angiography was performed 6 to 24 hours after randomization. The primary end point was a composite of death, shock, congestive heart failure, or reinfarction up to 30 days. RESULTS: The primary end point occurred in 116 of 939 patients (12.4%) in the fibrinolysis group and in 135 of 943 patients (14.3%) in the primary PCI group (relative risk in the fibrinolysis group, 0.86; 95% confidence interval, 0.68 to 1.09; P=0.21). Emergency angiography was required in 36.3% of patients in the fibrinolysis group, whereas the remainder of patients underwent angiography at a median of 17 hours after randomization. More intracranial hemorrhages occurred in the fibrinolysis group than in the primary PCI group (1.0% vs. 0.2%, P=0.04; after protocol amendment, 0.5% vs. 0.3%, P=0.45). The rates of nonintracranial bleeding were similar in the two groups. CONCLUSIONS: Prehospital fibrinolysis with timely coronary angiography resulted in effective reperfusion in patients with early STEMI who could not undergo primary PCI within 1 hour after the first medical contact. However, fibrinolysis was associated with a slightly increased risk of intracranial bleeding. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00623623.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

April 11, 2013

Volume

368

Issue

15

Start / End Page

1379 / 1387

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Time-to-Treatment
  • Ticlopidine
  • Thrombolytic Therapy
  • Tenecteplase
  • Recurrence
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, P. W., Gershlick, A. H., Goldstein, P., Wilcox, R., Danays, T., Lambert, Y., … STREAM Investigative Team, . (2013). Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med, 368(15), 1379–1387. https://doi.org/10.1056/NEJMoa1301092
Armstrong, Paul W., Anthony H. Gershlick, Patrick Goldstein, Robert Wilcox, Thierry Danays, Yves Lambert, Vitaly Sulimov, et al. “Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.N Engl J Med 368, no. 15 (April 11, 2013): 1379–87. https://doi.org/10.1056/NEJMoa1301092.
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379–87.
Armstrong, Paul W., et al. “Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.N Engl J Med, vol. 368, no. 15, Apr. 2013, pp. 1379–87. Pubmed, doi:10.1056/NEJMoa1301092.
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz H-R, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379–1387.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

April 11, 2013

Volume

368

Issue

15

Start / End Page

1379 / 1387

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Time-to-Treatment
  • Ticlopidine
  • Thrombolytic Therapy
  • Tenecteplase
  • Recurrence
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male